Navigation Links
Diabetes Drug May Boost Weight Loss in Obese Patients
Date:10/23/2009

Combo of diet, exercise and injections helped non-diabetics shed pounds, study finds

FRIDAY, Oct. 23 (HealthDay News) -- The diabetes drug liraglutide helps obese people without diabetes lose weight, researchers have found.

The study authors also reported that high doses of liraglutide were more effective at helping people shed pounds than the weight-loss drug orlistat.

In the study, which included 564 diabetes-free obese patients aged 18 to 65 at 19 sites in Europe, participants were randomly selected to receive one of four injected doses of liraglutide (1.2 milligrams, 1.8 milligrams, 2.4 milligrams or 3 milligrams) or a placebo once a day, or 120 milligrams of orlistat three times a day.

All of the patients also increased their levels of physical activity and followed a calorie-restricted diet, which allowed for about 500 calories less per day than they needed.

Weight loss among patients taking liraglutide doses of 1.2, 1.8, 2.4 and 3 milligrams was 4.8 kilograms (10.5 pounds); 5.5 kilograms (12 pounds); 6.3 kilograms (14 pounds), and 7.2 kilograms (15.8 pounds), respectively, compared with 4.1 kilograms (9 pounds) with orlistat and 2.8 kilograms (6 pounds)with placebo. Weight loss of more than 5 percent occurred in 76 percent of patients taking 3 milligrams of liraglutide, 44 percent of patients taking orlistat, and 30 percent of patients in the placebo group, the researchers found.

Reduced blood pressure was noted in all of the patients taking liraglutide. The groups taking 1.8 to 3 milligrams of liraglutide had an 84 percent to 96 percent reduction in the prevalence of prediabetes, which is poor blood glucose control that's not yet bad enough to qualify as diabetes.

Nausea and vomiting was more common among patients taking liraglutide than among those in the placebo group, the study authors noted.

"The results of this study indicate the potential benefit of liraglutide, in conjunction with an energy-deficit diet, in the treatment of obesity and associated risk factors," wrote Dr. Arne Astrup, of the department of human nutrition at the University of Copenhagen, Denmark, and colleagues.

Additional studies with a follow-up longer than 20 weeks are now needed to investigate the long-term risk/benefit profile of liraglutide, the study authors noted.

The study was released online Oct. 22 in advance of publication in an upcoming print issue of The Lancet.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases outlines the health risks of being overweight.



-- Robert Preidt



SOURCE: The Lancet, news release, Oct. 22, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Adverse housing conditions contribute to diabetes risk
2. RAND finds cases of undiagnosed diabetes drop sharply
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Discovery of sugar sensor in intestine could benefit diabetes
6. Despite overeating, morbidly obese mice gain protection against diabetes
7. Heart Attack Boosts Diabetes Risk
8. Obesity Doesnt Always Equal Diabetes
9. Sugary Sodas High in Diabetes-Linked Compound
10. Treating diabetes during pregnancy can break link to childhood obesity
11. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... Gout is like no other joint pain. It strikes suddenly, ... intense swelling and redness. It is triggered by the crystallization of uric acid within ... most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. , ...
(Date:2/10/2016)... MI (PRWEB) , ... February 10, 2016 , ... ... Apifiny® across their network of laboratory service centers across the country. Launched ... to aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... will attend the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted ... Greater Columbus Convention Center. , As the longest running and largest worker's ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable Allscripts ... and select appointments via Everseat’s free mobile app. , The partnership gives Everseat ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
Breaking Medicine Technology: